Document is current

Any future updates will be listed below

Correction: Assessing the Value of New Antimicrobials: Evaluations of Cefiderocol and Ceftazidime-Avibactam to Inform Delinked Payments by the NHS in England

Crossref DOI link: https://doi.org/10.1007/s40258-025-00979-4

Published Online: 2025-06-02

Published Print: 2025-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark